ReviewCJC open2025
Implementing Dyslipidemia Guidelines into Clinical Practice Following an Acute Coronary Syndrome: Challenges and Opportunities for Improvement.
Review in CJC open, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
4 citing papers in PubMed.
- Prevalence and Predictors of Lipoprotein(a) Measurement in Younger Patients Following ST-Elevation Myocardial Infarction.CJC open · 2026Article
- Real-world experience in the management of lipids in patients after an acute coronary syndrome.Journal of Taibah University Medical Sciences · 2026Article
- Secondary Prevention in STEMI Patients: Insights from a Regional Virtual STEMI Clinic.CJC open · 2026Article
- Intensive lipid-lowering therapy-related regression of a vulnerable plaque confirmed by serial optical coherence tomography: a case report.Frontiers in cardiovascular medicine · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Following an acute coronary syndrome (ACS), patients remain at a residual increased risk of adverse cardiovascular events. As such, secondary prevention strategies, including dyslipidemia management, are key in the delivery of post-ACS care. Multiple randomized controlled trials have highlighted the benefit of lipid-lowering therapies in reducing low-density lipoprotein cholesterol levels, an independent predictor of adverse cardiovascular events post-ACS. However, registries have demonstrated that post-ACS, a significant proportion of patients are not achieving guideline-recommended low-density lipoprotein target levels, and intensification of lipid-lowering therapies continues to be underutilized. This review assesses strategies in which post-ACS lipid management can be improved, in particular by standardizing follow-up care through dedicated post-ACS clinics.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.